Trial
NCT02393378
Namilumab vs Adalimumab in Participants With Moderate to Severe Early Rheumatoid Arthritis Inadequately Responding to Methotrexate
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Takeda
Collaborators
—
Condition
Rheumatoid Arthritis
Intervention
Namilumab
Why stopped
Strategic decision - to understand data from psoriasis study - NCT02129777 and wait for results of formal proof of concept study - NCT02379091.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-02-05